Nasal delivery of thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection

Many people remain at risk of being infected due to vaccine shortages and breakthrough infections with SARS-CoV-2 variants. We have developed a thermostable, egg yolk-derived intranasal antibody against the SARS-CoV-2 original, as well as variant strains, which can effectively prevent SARS-CoV-2 infection in a mouse model.

This antibody demonstrated good thermostability and broadly neutralizing activity in cells against multiple variants of concern. This low-cost vaccine supplement from vaccinated laying hens promises an option for use in high-risk populations.